Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:48:21 13/05/2026 am IST			5-day change	1st Jan Change
0.0690 ^AUD	-6.76%		-10.39%	-18.82%

07:17am	Neurizon Therapeutics receives ethics approval for Phase 1 Nuz-001 oral liquid formulation study	RE
06:27am	Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%	MT

Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets

Published on 01/20/2026 at 08:13 am IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Neurizon Therapeutics Limited

07:17am	Neurizon Therapeutics receives ethics approval for Phase 1 Nuz-001 oral liquid formulation study	RE
06:27am	Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%	MT
16/04	Neurizon Therapeutics Raises Nearly AU$3 Million to Reduce Entitlement Offer Shortfall; Shares Fall 7%	MT
16/04	Neurizon Therapeutics announces placement of entitlement offer shortfall to raise ~A$2.7 million	RE
01/04	Neurizon Therapeutics Says Preclinical Findings Show NUZ-001 Drug Candidate Raises Protein Clearance Activity in Neuronal Systems; Shares Rise 5%	MT
16/03	Neurizon Therapeutics says Michael Thurn resigns as managing director and CEO	RE
16/03	Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%	MT
05/03	Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease	MT
27/02	Neurizon Therapeutics Limited Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial	CI
25/02	Neurizon Therapeutics posts loss for half year attributable of A$5.5 million	RE
25/02	Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
20/01	Neurizon Therapeutics secures registered trademark protection for Neurizon® across all priority global markets	RE
02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

More about the company